<DOC>
	<DOCNO>NCT01411800</DOCNO>
	<brief_summary>The purpose study assess pharmacodynamic effect , pharmacokinetics , safety two oral formulation ( tablet capsule ) LX1033 normal healthy volunteer .</brief_summary>
	<brief_title>An Open-Label Study Two Formulations LX1033 Healthy Human Subjects</brief_title>
	<detailed_description />
	<mesh_term>Irritable Bowel Syndrome</mesh_term>
	<criteria>Adult subject age 18 55 year Vital sign acceptable Screening Body mass index ( BMI ) 18 35 kg/m^2 Screening Considered good health , determine Investigator Normal ECG finding Negative urine screen drug abuse negative breath test alcohol Negative hepatitis B surface antigen , hepatitis C antibody , HIV1 HIV2 antibody test within last 28 day Ability provide write informed consent Use medication ( include acetaminophen ) within 5 day dose Use investigational agent selective serotonin reuptake inhibitor ( SSRIs ) within 30 day study start Administration protein antibody within 90 day study start Donation loss great 450 mL blood within 45 day study start Known history hepatic disease significantly abnormal liver function test History alcoholism substance abuse within 3 year prior study start Participation clinical study within 30 day precede first dose study drug Positive serum pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>